Orlando Health
Brain Tumor Clinical Trials

For More Information

For more information contact : Nicholas Avgeropoulos, 813.745.4991

Phase I-II trial of Everolimus and Sorafenib in Patients with Recurrent High Grade Glioma

NCI 16-C-0011

  • Division CORO Onc Neuro
  • IRB Status Active: Open to enrollment
  • Principal Investigator Avgeropoulos, Nicholas MD
  • Type Treatment (drug or other)
    Oncology Study Type Treatment – Cancer
  • Drug/Device Drug: Phase I; Drug: Phase II
  • Age Group Adult
  • Secondary Protocol No. previous BTTC09-01
  • Title (web) Everolimus and Sorafenib in Recurrent High Grade Glioma
  • Objective
    The goal of this study to learn if the combination of everolimus and sorafenib can help to control malignant glioma.
  • Key Eligibility Patients with Recurrent High Grade Glioma
  • Applicable Disease Sites Brain
  • Therapies Involved Chemotherapy
  • Therapies Drug: Everolimus
    Drug: Everolimus
  • ClinicalTrials.gov ID NCT01434602
  • Target 10
  • Initial Approval Date 10/23/2012
  • SIV
  • Initial Protocol Version Date 5/14/2012
  • Current Protocol Version Date 12/17/2015
  • Source Cooperative group
  • Sponsor NCI Brain Tumor Trials Collaborative (BTTC)

Florida Center for Brain Tumor Research

FCBTR current

  • Division CORO Onc Neuro
  • IRB Status Active: Open to enrollment
  • Principal Investigator Avgeropoulos, Nicholas MD
  • Type Specimen repository; Registry (prospective)
  • Drug/Device Not applicable
  • Age Group Adult
  • Title (web) Brain tumor tissue collection
  • Objective
    This proposal is part of a multidisciplinary and legislatively-mandated statewide effort to establish a world-class Brain Tumor Tissue Repository and Registry in Florida that will yield internationally competitive research. It is designed to maximize the use of each specimen and facilitate collaboration and discovery.
  • Key Eligibility
    Collect and bank tissue, blood, and cerebrospinal fluid from patients with all varieties of brain tumors and from control patients who are undergoing neurological surgery for other reasons.
  • Routing ufhccoh.com
  • Service Line UFHCCOH Brain and Spine Tumor CenterSection (Service Line) UFHCCOH: Subsection N/A for website. See CORO with questions.
  • ClinicalTrials.gov ID NCT00811148
  • Initial Approval Date 6/18/2015
  • Initial Protocol Version Date 06/16/2015
  • Current Protocol Version Date 3/3/2016

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation

Protocol Abbrev A071102

  • Division CORO Onc Neuro
  • IRB Status Active: Open to enrollment
  • Principal Investigator Avgeropoulos, Nicholas MD
  • Subinvestigators Ramakrishna, Naren MD
  • Type Treatment (drug)
  • Oncology Study Type Treatment – Cancer
  • Drug/Device Drug: Phase II; Drug: Phase III
  • Age Group Adult
  • Title (web) Veliparib Or Placebo In Newly Diagnosed Glioblastoma With MGMT
  • Objective
    Test whether the experimental combination of ABT-888 (veliparib) combined with TMZ, compared to the control of placebo combined with TMZ, significantly extends overall survival in newly diagnosed GBM patients with tumor MGMT promoter hypermethylation.
  • Key Eligibility
    Newly diagnosed GBM patients with tumor MGMT promoter hypermethylation
  • Applicable Disease Sites GBM
  • Therapies Involved Medication
  • ClinicalTrials.gov ID NCT02152982
  • Initial Approval Date 7/23/2015
  • Initial Protocol Version Date 04/15/2015

A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined with Bevacizumab vs. Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma

Protocol Abbrev VB-111-215

  • Division CORO Onc Neuro
  • IRB Status Active: Open to enrollment
  • IRB No. 15.083.07
  • Principal Investigator Avgeropoulos, Nicholas MD
  • Oncology Study Type Non-Treatment – Procedure/Treatment Dependent
  • Drug/Device Drug: Phase III
  • Age Group Adult
  • Secondary Protocol No. VB-111-215
  • Title (web) Study of VB-111 in Recurrent Glioblastoma
  • Objective
    To evaluate the efficacy, safety and tolerability of VB-111 every 2 months combined with bevacizumab every 2 weeks in recurrent GBM patients compared to patients who receive bevacizumab every 2 weeks monotherapy
  • Key Eligibility
    First or second progression of Glioblastoma after standard treatment with temozolomide and radiation
  • Applicable Disease Sites Brain
  • Section (Service Line) UFHCCOH: Subsection N/A for website. See CORO with questions.
  • ClinicalTrials.gov ID NCT02511405
  • Initial Approval Date 12/3/2015
  • Initial Protocol Version Date 3/3/2015